Persistence of chronic cough in a community-based population
- PMID: 32494575
- PMCID: PMC7248348
- DOI: 10.1183/23120541.00229-2019
Persistence of chronic cough in a community-based population
Abstract
Chronic cough causes significant impairment in the quality of life and is often immune to treatment. Previous studies about its persistence have focused on patients managed in special cough clinics. Little is known about the persistence of chronic cough in unselected populations. In this prospective follow-up study, we investigated factors that predict the persistence of cough at 12-month follow-up in a community-based study of subjects with chronic cough. The first e-mail survey in 2017 included a questionnaire about current cough and its risk factors. The 264 subjects who reported chronic cough were sent a follow-up questionnaire 12 months later. The response rate was 77.7% (205 subjects), of whom 165 subjects (80.5%) still had cough in 2018. In multivariate analysis, the following baseline factors predicted the persistence of cough at 12 months; gastro-oesophageal reflux disease (adjusted OR (aOR) 5.02 (95% CI 1.10-22.83)), presence of a chemical trigger (aOR 2.88 (95% CI (1.20-7.00)), duration of cough more than 1 year (aOR 2.80 (95% CI 1.27-6.22)), frequent somatic symptoms (aOR 1.31 (95% CI 1.07-1.59)), and low number of family members (aOR 0.71 (95% CI 0.52-0.98)). In conclusion, most patients with chronic cough still suffer from cough 1 year later. The presence of gastro-oesophageal reflux disease is the main predictor for the persistence of cough.
Copyright ©ERS 2020.
Conflict of interest statement
Conflict of interest: A.M. Lätti reports grants from The Kuopio Region Respiratory Foundation, The Research Foundation of the Pulmonary Diseases, the Foundation of the Finnish Anti-Tuberculosis Association, The Väinö and Laina Kivi Foundation and the state subsidy of the Kuopio University Hospital during the conduct of the study, and personal fees from Orion, Boehringer Ingelheim, Roche and AstraZeneca to visit international scientific meetings outside the submitted work. Conflict of interest: J. Pekkanen has nothing to disclose. Conflict of interest: H.O. Koskela reports grants from Kuopion Seudun Hengityssäätiö Foundation and Hengityssairauksien Tutkimussäätiö during the conduct of the study; personal fees from Mundipharma Ltd, Orion Pharma Ltd, Oy, Eli Lilly Finland Ltd and Boehringer Ingelheim Finland Ltd as payments for giving scientific lectures in gatherings organised by medical companies, personal fees from Takeda Leiras Ltd, Boehringer Ingelheim Ltd, Mundipharma Ltd and AstraZeneca Ltd to visit international scientific meetings, and owning shares of Orion Pharma Ltd worth €22 000.
Figures
References
-
- Centers for Disease Control and Prevention. National Ambulatory Medical Care Survey: 2010 Summary Tables. Atlanta, Centers for Disease Control and Prevention, 2014.
LinkOut - more resources
Full Text Sources